EIF4A2 and hepatocellular carcinoma: Moreover, this is the first study to demonstrate in the setting of HCC that Rapalink-1-induced inhibition of mTOR signaling can be achieved through suppression of two key downstream substrates, p-RPS6Ser235/236 and p-4EBP1Thr37/46, even in the presence of eIF4A inhibitors.